Biotech Values

[corpstrat]

Amicus - Shire: Thank you for jogging the memory. It's interesting strategy to invest in a quasi-rival product, though, as you say, perhaps they see it a s product that can work for pts for whom ERT does not work. I hope they don't plan to smother Plicera, a cynical strategy that is not inconceivavble in this game.

Genzyme's price umbrella is outrageously high, making for an attractive market for Shire with its own candidate and Plicera?